The big story in the digestives space is the switch and launch in May of Pfizer’s Nexium 24HR. In a little more than 10 weeks on the shelf, the brand has generated $53.6 million in sales across total U.S. multi-outlets for the 52 weeks ended Aug. 10, according to IRI.
The resurgence of iconic pain relief brands Tylenol and Excedrin continue to contribute to the slight growth across internal analgesic tablets. It’s a $3.2 billion book of business across U.S. multi-outlets, according to IRI, that is up slightly by 0.8% for the 52 weeks ended Aug. 10.
As the Food and Drug Administration begins to explore ways to improve its user-fee program for generic drugs, the Generic Pharmaceutical Association and its members have weighed in with suggestions on how to shore up the law to ensure that it helps bring generics to market faster and provides benefits across the entire healthcare system.